Literature DB >> 15516842

Ashkenazi Jewish genetic disorders.

Joel Charrow1.   

Abstract

The frequency of several genes responsible for 'single-gene' disorders and disease predispositions is higher among Ashkenazi Jews than among Sephardi Jews and non-Jews. The disparity is most likely the result of founder effect and genetic drift, rather than heterozygote advantage. The more common Mendelian Ashkenazi Jewish genetic disorders are summarized, and examples of variable expressivity and penetrance, inconsistent genotype-phenotype correlation, and potential modifiers are presented. The importance of genetic counseling in both the pre- and post-test phases of population screening is emphasized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516842     DOI: 10.1007/s10689-004-9545-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  9 in total

1.  The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease.

Authors:  J Ekstein; H Katzenstein
Journal:  Adv Genet       Date:  2001       Impact factor: 1.944

Review 2.  Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.

Authors:  Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Ainu Prakash-Cheng; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Neal J Weinreb
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406

Review 3.  Miglustat. Oxford GlycoSciences/Actelion.

Authors:  Robin H Lachmann
Journal:  Curr Opin Investig Drugs       Date:  2003-04

4.  Protection afforded by sickle-cell trait against subtertian malareal infection.

Authors:  A C ALLISON
Journal:  Br Med J       Date:  1954-02-06

Review 5.  The genetics of primary dystonias and related disorders.

Authors:  Andrea H Németh
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

6.  Enzyme polymorphisms in man.

Authors:  H Harris
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-03-22

Review 7.  Gaucher disease. Enzymology, genetics, and treatment.

Authors:  G A Grabowski
Journal:  Adv Hum Genet       Date:  1993

8.  Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.

Authors:  M Jeyakumar; T D Butters; M Cortina-Borja; V Hunnam; R L Proia; V H Perry; R A Dwek; F M Platt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

9.  Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation.

Authors:  S B Bressman; D de Leon; P L Kramer; L J Ozelius; M F Brin; P E Greene; S Fahn; X O Breakefield; N J Risch
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

  9 in total
  17 in total

1.  Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population.

Authors:  Steven M Bray; Jennifer G Mulle; Anne F Dodd; Ann E Pulver; Stephen Wooding; Stephen T Warren
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-26       Impact factor: 11.205

2.  Health effects of human population isolation and admixture.

Authors:  Igor Rudan
Journal:  Croat Med J       Date:  2006-08       Impact factor: 1.351

Review 3.  Working up policy: the use of specific disease exemplars in formulating general principles governing childhood genetic testing.

Authors:  Paula Boddington; Susan Hogben
Journal:  Health Care Anal       Date:  2006-03

4.  Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population.

Authors:  Iris Schrijver; Maigi Külm; Phyllis I Gardner; Eugene P Pergament; Morris B Fiddler
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

5.  A study of Kibbutzim in Israel reveals risk factors for cardiometabolic traits and subtle population structure.

Authors:  Einat Granot-Hershkovitz; David Karasik; Yechiel Friedlander; Laura Rodriguez-Murillo; Rajkumar Dorajoo; Jianjun Liu; Anshuman Sewda; Inga Peter; Shai Carmi; Hagit Hochner
Journal:  Eur J Hum Genet       Date:  2018-08-14       Impact factor: 4.246

6.  Whole-Exome Sequencing Identifies a Novel Homozygous Frameshift Mutation in the MTMR2 Gene as a Causative Mutation in a Patient with Charcot-Marie-Tooth Disease Type 4B1.

Authors:  Tameemi Abdalla-Moady; Amir Peleg; Orit Sadeh; Khader Badarneh; Fuad Fares
Journal:  Mol Neurobiol       Date:  2017-05-16       Impact factor: 5.590

7.  The incidence of inherited metabolic disorders in the West Midlands, UK.

Authors:  S Sanderson; A Green; M A Preece; H Burton
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

8.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

9.  A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations.

Authors:  Carol J Gallione; Ann Solatycki; Issam A Awad; James L Weber; Douglas A Marchuk
Journal:  Genet Med       Date:  2011-07       Impact factor: 8.822

10.  Saturation of the human phenome.

Authors:  Mark E Samuels
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.